139 search results for: patient burden

The Compounded <b>Burden</b> of CRSwNP and Asthma
Pulmonology
The Compounded Burden of CRSwNP and Asthma
interactivity

This infographic illustrates the compounded burden of coexisting CRSwNP and asthma and explains how type 2 inflammation underlies both conditions and impacts clinical outcomes in patients.

View more
ADVENT On Air | More Than Just Difficulty Swallowing: EoE <b>Burden</b> and Diagnosis
Gastroenterology
ADVENT On Air | More Than Just Difficulty Swallowing: EoE Burden and Diagnosis
Podcast

Hear Dr. Wechsler and Prof. Bredenoord discuss the multifaceted burden of EoE and how to overcome challenges in identifying EoE in clinical practice.

View more
ADVENT on Air: OCS in CRSwNP Podcast
Rhinology
ADVENT on Air: OCS in CRSwNP Podcast
Podcast

Listen to experts, Dr. Amber Luong and Dr. Marjolein Cornet, discuss the significant burden of oral corticosteroid (OCS) use in chronic rhinosinusitis with nasal polyps (CRSwNP) and its short-term, long-term, and cumulative risks, particularly for patients with coexisting conditions like asthma. Experts highlight the need for improved multidisciplinary approaches and OCS-sparing strategies to optimize patient care.

View more
Compounded <b>Burden</b> of Co-existing Type 2 Airway Diseases
Pulmonology
Compounded Burden of Co-existing Type 2 Airway Diseases
expert video

In this video soundbite from the EAACI 2025 symposium, Dr. Brian Lipworth discusses that co-existing type 2 inflammatory diseases are common in patients with CRSwNP​ & increasing severity of asthma is associated with higher severity of CRS and prevalence of nasal polyps. Additionally, he explains that patient burden is substantially greater when asthma and CRSwNP are co-existing.

View more
EADV 2025
On Demand
The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?

Join Professors Jean-David Bouaziz, Amy Paller, and Alan Irvine for a dynamic presentation on the multifaceted burden of atopic dermatitis, the evolving concept of disease modification, and how targeted systemic therapies may help improve long-term patient outcomes.

ADVENT at EADV 2026
Congress
29
September
2026
Congress
ADVENT at EADV 2026

Please join the ADVENT program at EADV 2026 for educational sessions on AD, PN, and CSU! Experience 3 high-impact sessions led by world-renowned experts, bridging scientific innovation with real-world clinical outcomes.

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease <b>Burden</b>
Dermatology
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
expert video

In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.

View more
Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice
Dermatology
Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice
expert video

This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.

View more
ERS 2026 | Distal Airways, Central Role? Clinical Insights Into Type 2 Severe Asthma
Pulmonology
ERS 2026 | Distal Airways, Central Role? Clinical Insights Into Type 2 Severe Asthma
expert video

Join experts Frederik Trinkmann, Monica Kraft, and Arnaud Bourdin on an ADVENT educational symposium, “Distal Airways, Central Role? Clinical Insights Into Type 2 Severe Asthma."

View more
ERS-ISIAN 2025 | Type 2 Inflammation: Links with Severe/Uncontrolled CRSwNP
Rhinology
ERS-ISIAN 2025 | Type 2 Inflammation: Links with Severe/Uncontrolled CRSwNP
expert video

Prof. Vibeke Backer provides an insightful presentation on the association of type 2 inflammation and the pathogenesis and management of severe and uncontrolled CRSwNP.

View more
Breaking the Cycle of AD in Adults: Minimizing Cumulative <b>Burden</b> Beyond Skin and Achieving Sustained Disease Control
Dermatology
Breaking the Cycle of AD in Adults: Minimizing Cumulative Burden Beyond Skin and Achieving Sustained Disease Control
expert video

Prof. Tilo Biedermann discusses the key roles of type 2 cytokines IL-4, IL-13, and IL-31 in the pathophysiology of atopic dermatitis. He then describes how these cytokines can be targeted with systemic therapies to elicit long-term disease control and reduce the burden of atopic and non-atopic comorbidities, which are meaningful outcomes for patients with uncontrolled disease.

View more